Search Results - "Creelan, B C"

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma

    Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma by Schabath, M B, Welsh, E A, Fulp, W J, Chen, L, Teer, J K, Thompson, Z J, Engel, B E, Xie, M, Berglund, A E, Creelan, B C, Antonia, S J, Gray, J E, Eschrich, S A, Chen, D-T, Cress, W D, Haura, E B, Beg, A A

    Published in Oncogene (16-06-2016)
    “…While mutations in the KRAS oncogene are among the most prevalent in human cancer, there are few successful treatments to target these tumors. It is also…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations

    Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations by Creelan, B.C., Yeh, T., Kim, S.-W., Nogami, N., Kim, D.-W., Chow, L.Q., Kanda, S., Taylor, R., Tang, W., Tang, M., Angell, H.K., Roudier, M.P., Marotti, M., Gibbons, D.L.

    Published in Annals of oncology (01-04-2019)
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    84OPhase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations

    84OPhase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations by Creelan, B C, Yeh, T, Kim, S-W, Nogami, N, Kim, D-W, Chow, L Q, Kanda, S, Taylor, R, Tang, W, Tang, M, Angell, H K, Roudier, M P, Marotti, M, Gibbons, D L

    Published in Annals of oncology (01-04-2019)
    Get full text
    Journal Article
    Save to List
    Saved in:
  4. 4
    Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma

    Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma by Creelan, Ben C, Antonia, Scott, Noyes, David, Hunter, Terri B, Simon, George R, Bepler, Gerold, Williams, Charles C, Tanvetyanon, Tawee, Haura, Eric B, Schell, Michael J, Chiappori, Alberto

    Published in Journal of immunotherapy (1997) (01-10-2013)
    “…We created a vaccine in which irradiated allogeneic lung adenocarcinoma cells are combined with a bystander K562 cell line transfected with hCD40L and hGM-CSF…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  5. 5
    Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in stage III non-small cell lung cancer

    Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in stage III non-small cell lung cancer by Creelan, B. C., Bepler, G., Antonia, S., Garrett, T., Soliman, H. H.

    Published in Journal of clinical oncology (20-05-2011)
    “…Abstract only…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: